CTOs on the Move


 
Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel`s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin`s development and commercialization in ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.poxel.com
  • One Broadway 14th Floor
    Cambridge, MA USA 02142
  • Phone: 617.758.4100

Executives

Name Title Contact Details

Similar Companies

GVB Biopharma

GVB Biopharma operates two state-of-the-art hemp extraction and white labeling facilities in Central Oregon and Las Vegas, Nevada.

Steakholder Foods

Meat. It’s an ancient and universal tradition. A story of human evolution and progress, family and culture. A story of our relationship with animals. With the

Avanir

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.

BioPharm Engineered Systems

BioPharm Engineered Systems is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cydan

Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.